Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GlaxoSmithKline PharmaceuticalsNSE:GLAXO -2.05%73 Return-on-Tangible-Asset is 25.74% as of Mar. 2026, which is 90% above its 10-year median of 13.56. GuruFocus rates NSE:GLAXO with a GF Score™ of 73/100 and a GF Value™ of ₹2,631.55 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,007 Drug Manufacturers companies, GlaxoSmithKline Pharmaceuticals ranks better than 96.82% on this metric.
The historical rank and industry rank for GlaxoSmithKline Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
NSE:GLAXO'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 2.69 Med: 13.56 Max: 44.19
Current: 25.75
During the past 13 years, GlaxoSmithKline Pharmaceuticals's highest Return-on-Tangible-Asset was 44.19%. The lowest was 2.69%. And the median was 13.56%.
NSE:GLAXO's Return-on-Tangible-Asset is ranked better than 96.82% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs NSE:GLAXO: 25.75
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
GlaxoSmithKline Pharmaceuticals Return-on-Tangible-Asset Related Terms
GlaxoSmithKline Pharmaceuticals Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GLAXO vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pharmaceuticals Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 25.74% mean?
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a Return-on-Tangible-Asset of 25.74% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. This is 90% above median its historical median of 13.56. Over the past decade, GlaxoSmithKline Pharmaceuticals' Return-on-Tangible-Asset has ranged from 2.69 to 44.19. According to the industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #32 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 3.2%.
Is GlaxoSmithKline Pharmaceuticals' Return-on-Tangible-Asset too high?
GlaxoSmithKline Pharmaceuticals' current Return-on-Tangible-Asset of 25.74% is 90% above median its 10-year median of 13.56. Over the past 10 years, this metric has ranged from a low of 2.69 to a high of 44.19. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. GlaxoSmithKline Pharmaceuticals' value of 25.74% is 714.6% above this industry median. Based on the distribution chart, GlaxoSmithKline Pharmaceuticals ranks #32 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #32 out of 1007 companies for Return-on-Tangible-Asset. This places GlaxoSmithKline Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.16. GlaxoSmithKline Pharmaceuticals' value of 25.74% is 714.6% above this benchmark. Historically, GlaxoSmithKline Pharmaceuticals' own Return-on-Tangible-Asset has ranged from 2.69 to 44.19 over the past decade. While the company's 10-year median is 13.56 vs. the industry median of 3.16, GlaxoSmithKline Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pharmaceuticals's current Return-on-Tangible-Asset of 25.74% is 714.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pharmaceuticals's current Return-on-Tangible-Asset is 25.74%, which is 90% above median its own 10-year median of 13.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,631.55, compared to a current price of ₹2,454.80 — trading 6.7% below its estimated fair value. The current Return-on-Tangible-Asset is 25.74%, which is 90% above median its 10-year median of 13.56 and 714.6% above the Drug Manufacturers industry median of 3.16. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current Return-on-Tangible-Asset is 25.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹2,454.80 is trading 6.7% below its estimated GF Value™ of ₹2,631.55.
GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:GLAXO:
Return-on-Tangible-Asset: 25.74% (90% above median its 10-year median of 13.56)
GF Value™: ₹2,631.55 vs. price of ₹2,454.80 (6.7% below fair value)
Industry Position: 714.6% above the Drug Manufacturers median (#32 of 1007)
No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pharmaceuticals Business Description
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
73GF Score
Get the complete analysis for NSE:GLAXO
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAXO has been successfully added to your 
